Biogen Inc. (BIIB) Stifel 2025 Virtual CNS Forum Conference (Transcript)
Biogen Inc. ( NASDAQ: BIIB) Stifel 2025 Virtual CNS Forum Conference March 18, 2025 10:15 AM ET Great. Good morning, everybody. Happy to be moderating my annual panel where Priya has to listen to me ...
Asian Development Bank1d
Building Resilience in Education Systems
Building Resilience in Education Systems presents 13 chapters on strengthening education system resilience, written specifically for policy makers and practitioners. The book examines diverse contexts ...
Unleased lab space. Plunging valuations. Layoffs. In Massachusetts, the biotech slump is taking its toll.
There are few signs the industry responsible for more than 115,000 Massachusetts jobs is pulling out of its four-year downswing.
Pharmabiz5d
Biogen begins TRANSCEND phase 3 study of felzartamab to treat late antibody-mediated rejection in kidney transplant patients
Cambridge, Massachusetts Thursday, March 13, 2025, 10:00 Hrs [IST] ...
PipelineReview.com6d
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
CAMBRIDGE, MA, USA I March 11, 2025 I Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase ...
Biogen begins dosing in trial of felzartamab for kidney transplant patients with AMR
In Part A of the trial, subjects will be given nine intravenous infusions of either the drug or placebo over a six-month period.